Status and phase
Conditions
Treatments
About
Viagra (Sildenafil citrate) is an orally active selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) which is used for the treatment of erectile dysfunction (ED). Objectives:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects who have given written informed consent to participate in the study.
Men aged 18-65 years old.
Weight range 50-100 Kg.
Subjects must be in a stable relationship with the same partner for at least 6 months and willing to attempt sexual intercourse.
Normal pre-operative erectile function (defined as IIEF-EF ≥ 26) without the use of therapy or devices for the improvement of erections.
Prostatic Specific Antigen (PSA) lower than 10 ng/ml.
Clinical prostate cancer stage T1c or T2.
Biopsy Gleason sum < 8.
Able to read, understand and provide signed informed consent.
Intra-operative inclusion criteria:
Bilateral nerve sparing radical prostatectomy (both open and robotic assisted radical prostatectomy are accepted) as defined by the surgeon.
Post-operative inclusion criteria:
Histologically-confirmed, organ-confined prostate cancer disease (defined as, Gleason 6 or 7 and, pathological stage T2 or T3a R0 N0).
Exclusion criteria
Subjects presenting with any of the following will not be included in the trial:
Primary purpose
Allocation
Interventional model
Masking
200 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal